Physician profile
James Winegar
NPI 1578566360
$2,508.31
in general payments reported to CMS, 2019-2025
30 companies · $18.37 in 2025
The $18.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $507 · 2021: $802 · 2022: $425 · 2023: $210 · 2024: $28.03 · 2025: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $340.17 | 2019-2023 | Breztri |
| Abbvie INC. | $286.18 | 2020-2023 | Vraylar |
| Abbott Laboratories | $200.31 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $132.61 | 2019-2022 | |
| Lilly USA, LLC | $131.67 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $122.74 | 2019-2021 | |
| Amarin Pharma, INC. | $114.47 | 2020-2021 | |
| Astellas Pharma US INC | $88.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.51 | 2020-2022 | |
| Esperion Therapeutics, INC. | $59.55 | 2021 | |
| Allergan, INC. | $51.90 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $47.35 | 2019-2021 | |
| Pfizer INC. | $45.65 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.67 | 2019 | |
| Glaxosmithkline, LLC. | $38.39 | 2019 | |
| Inogen, INC. | $36.82 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Bayer Healthcare Pharmaceuticals INC. | $36.50 | 2021 | |
| Almatica Pharma LLC | $33.14 | 2021-2022 | |
| Eisai INC. | $29.96 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.56 | 2020 | |
| Merck Sharp & Dohme LLC | $24.25 | 2022 | |
| Shire North American Group INC | $17.15 | 2019 | |
| Circassia INC. | $16.33 | 2019 | |
| Horizon Therapeutics Plc | $15.63 | 2020 | |
| Antares Pharma, INC. | $15.00 | 2022 | |
| Alkermes, INC. | $14.15 | 2023 | Lybalvi |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Winegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.